A patient-led initiative for rare disease hereditary haemorrhagic telangiectasia (HHT) has won the inaugural Prix Galien ...

Dojolvi was approved in the US in 2020 and was also launched in Japan earlier this year. Ultragenyx recorded sales of $45 ...

Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives, ...

The WuXi agreement gives Fresenius "full strategic flexibility" to choose which biosimilar candidates to develop and gives ...

Hutchmed and AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven, EGFR-mutated lung cancer, a few ...

On 3 and 4 December 2026, Florence will host ISMAI 2026, the International Symposium on Medical AI, organised by the ...

Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid) has been granted an accelerated approval by the FDA as a ...

As the only dedicated forum convening the global liquid biopsy community, the 11th Liquid Biopsy for Precision Oncology ...

AbbVie has filed for FDA approval of its T-cell engager (TCE) etentamig in relapsed or refractory multiple myeloma, a key pillar of its strategic expansion into oncology. The drug, described as a ...

Eli Lilly has added another arrow to the quiver of its new diabetes and weight-loss therapy retatrutide, comprehensively outperforming Novo's rival Ozempic in a head-to-head trial. Results from the ...

Reforms to the regulatory framework for clinical research in the UK are starting to deliver, with delivery times slashed by 35%, according to new government figures. According to the Department of ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set to ...